Modality
mRNA
MOA
HPK1i
Target
B7-H3
Pathway
RNA Splicing
SLECLLUrothelial Ca
Development Pipeline
Preclinical
Nov 2025
→ Feb 2027
PreclinicalCurrent
NCT04058000
351 pts·CLL
2025-11→2025-12·Active
NCT07815580
1,670 pts·SLE
2025-11→2027-02·Active
2,021 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-014mo agoInterim· CLL
2027-02-1611mo awayInterim· SLE
Trial Timeline
2026Q2Q3Q42027
Preclinical
Active
Preclinical
Active
Catalysts
Interim
2025-12-01 · 4mo ago
CLL
Interim
2027-02-16 · 11mo away
SLE
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04058000 | Preclinical | CLL | Active | 351 | EASI-75 |
| NCT07815580 | Preclinical | SLE | Active | 1670 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 |